Pharmaceuticals, Biotechnology and Life Sciences
Verona Pharma has completed patient enrolment for the Phase IIa dose-finding study of RPL554 in asthma and the Phase IIa combination study of RPL554 in chronic obstructive pulmonary disease (COPD), in which the drug is being administered in addition to standard of care bronchodilators.
OptiBiotix Health has announced the filing of two new patents covering its cholesterol reducing product. This increases the number of patents from nine to eleven.
Finland’s Faron Pharmaceuticals Oy, a clinical stage biopharmaceutical company, has entered into an agreement with Swiss-based Selexis SA for producing Novel Cancer Immunotherapy Clevegen.
Bayer CropScience has reached an important milestone towards the market introduction of its innovative insecticide Sivanto prime in Europe.
Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Cosentyx(TM) (secukinumab)…
Dechra has announced that on the closing date of its Takeover Offer to acquire the shares in Genera not owned by…
Allergan plc has completed the acquisition of AqueSys, Inc. a clinical-stage medical device company focused on developing ocular implants that…
Quantum Pharma has signed an out-licensing agreement with a German pharmaceutical company for its first licensed product, a cholecalciferol 20 000IU capsule, marketed in the UK under the brand name Aviticol.
Physiomics plc, the Oxford, UK based systems biology company has signed a new Virtual Tumour deal with a new pharmaceutical company, the 4th large pharma customer for this service.
Allergan’s researchers have presented data at IDWeek from the International Network for Optimal Resistance Monitoring (INFORM) program that monitors the prevalence of resistant bacteria and changing trends of resistance, as well as the in vitro activity of antibiotics against these pathogens.